By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
Figure out How to Upgrade Your Gold Speculation Portfolio: Vital Bits of knowledge and Strategies - 29 Under-The-Radar Malaysian Islands To Consider Instead Of Thailand Or Indonesia
- 3Minneapolis ICE shooting: Woman dies after federal agent opens fire on her vehicle amid immigration crackdown
- 4Nuno Loureiro, MIT physicist, fatally shot at home; police investigate
- 5Figure out How to Pick the Right Dental specialist for Your Dental Inserts
- 7 Peculiar Ways Of starting Your Imagination: Motivation Has Never Been This Good times
- NASA wants to build a base on the Moon by the 2030s – how and why it plans to build up to a long-term lunar presence
- A mom stopped giving her kids snacks — and sparked a debate about eating habits
- Volkswagen Plant Could Pivot From Building Cars to Supporting Iron Dome Systems
- The most effective method to Alter Your Savvy Bed for A definitive Rest Insight
- Iran, Hezbollah fire rockets at Israel during Passover celebrations
- UK forecast to face weaker growth and higher inflation from Iran war
- Wolf Bites Woman in Shocking Attack at Busy Shopping Center
- How Mars 'punches above its weight' to influence Earth's climate
